These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1903 related items for PubMed ID: 11217867

  • 1. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N, Foster RH, Olney R, Plosker GL.
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [Abstract] [Full Text] [Related]

  • 2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [Abstract] [Full Text] [Related]

  • 3. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH, Goa KL.
    Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
    [Abstract] [Full Text] [Related]

  • 4. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T, Perry CM.
    Drugs; 2004 Jun; 64(15):1715-36. PubMed ID: 15257633
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V, Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine.
    JAMA; 2003 Nov 26; 290(20):2693-702. PubMed ID: 14645311
    [Abstract] [Full Text] [Related]

  • 6. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.
    Encephale; 2004 Nov 26; 30(5):417-24. PubMed ID: 15627046
    [Abstract] [Full Text] [Related]

  • 7. Risperidone. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH, Goa KL.
    Pharmacoeconomics; 1998 Jul 26; 14(1):97-133. PubMed ID: 10182198
    [Abstract] [Full Text] [Related]

  • 8. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.
    Fulton B, Goa KL.
    Drugs; 1997 Feb 26; 53(2):281-98. PubMed ID: 9028746
    [Abstract] [Full Text] [Related]

  • 9. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.
    Am J Psychiatry; 2002 Feb 26; 159(2):255-62. PubMed ID: 11823268
    [Abstract] [Full Text] [Related]

  • 10. Olanzapine: an atypical antipsychotic for schizophrenia.
    Lund BC, Perry PJ.
    Expert Opin Pharmacother; 2000 Jan 26; 1(2):305-23. PubMed ID: 11249551
    [Abstract] [Full Text] [Related]

  • 11. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
    Almond S, O'Donnell O.
    Pharmacoeconomics; 2000 Apr 26; 17(4):383-9. PubMed ID: 10947493
    [Abstract] [Full Text] [Related]

  • 12. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
    Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G.
    Pharmacoeconomics; 1999 May 26; 15(5):469-80. PubMed ID: 10537964
    [Abstract] [Full Text] [Related]

  • 13. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS, Spencer CM.
    CNS Drugs; 1998 Apr 26; 9(4):325-40. PubMed ID: 27521016
    [Abstract] [Full Text] [Related]

  • 14. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
    Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM, HGDH Study Group.
    Am J Psychiatry; 2003 Aug 26; 160(8):1396-404. PubMed ID: 12900300
    [Abstract] [Full Text] [Related]

  • 15. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.
    Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A.
    Pharmacoeconomics; 2000 Dec 26; 18(6):567-79. PubMed ID: 11227395
    [Abstract] [Full Text] [Related]

  • 16. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE.
    Am J Manag Care; 1998 Mar 26; 4(3):345-55. PubMed ID: 10178497
    [Abstract] [Full Text] [Related]

  • 17. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
    Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD.
    J Clin Psychiatry; 2001 Apr 26; 62(4):231-8. PubMed ID: 11379836
    [Abstract] [Full Text] [Related]

  • 18. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
    Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM.
    J Clin Psychiatry; 2003 Aug 26; 64(8):898-906. PubMed ID: 12927004
    [Abstract] [Full Text] [Related]

  • 19. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
    Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA.
    Neuropsychopharmacology; 2004 Jan 26; 29(1):133-45. PubMed ID: 14583740
    [Abstract] [Full Text] [Related]

  • 20. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
    Taylor DM, Wright T, Libretto SE, Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) U.K. Investigator Group.
    J Clin Psychiatry; 2003 May 26; 64(5):589-97. PubMed ID: 12755664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 96.